A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)

This study is currently recruiting participants.

Verified by BioSpherix, April 2008

First Received: March 21, 2007 Last Updated: April 29, 2008 History of Changes

Sponsors and Collaborators:	BioSpherix Spherix
Information provided by:	BioSpherix
ClinicalTrials.gov Identifier:	NCT00451477

Purpose

The purpose of this trial is to evaluate the effectiveness and safety of Naturlose (Tagatose) for glycemic control in people with Type 2 diabetes who are not taking other medications for the condition and who are under diet control and exercise.

The study will last approximately one year. HbA1c will be monitored every 2 months after entry into the study. Safety and tolerance for tagatose will be assessed every 2 months throughout the study. A total of 14 visits will be made to the study site.

Condition	Intervention	Phase
Type 2 Diabetes	Drug: Tagatose	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects With Type 2 Diabetes Under Diet Control and Exercise

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Diets Exercise and Physical Fitness

U.S. FDA Resources

Further study details as provided by BioSpherix:

Primary Outcome Measures:

To evaluate a placebo-subtracted treatment effect of tagatose in glycemic control determined by a statistically significant decrease in hemoglobin A1c (HbA1c) levels.

Estimated Enrollment:	426
Study Start Date:	April 2007

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetics in accordance with WHO.
Male and female patients, between 18 and 75 years of age.
Diabetic patients who are not on medication for the disease. Patients may be treated with diet and exercise.
Normal blood creatine clearance and normal liver function test results.
BMI less than or equal to 45kg/m2

Exclusion Criteria:

Treatment with sulfonylurea (e.g., Glyburide, Glipizide, Glimepiride, Chlorpropamide, Tolazamide, Acetohexamide, or Tolbutamide), TZDs, metformin, acarbose, Byetta, insulin, and any antidiabetic medications within the prior 3 months.
Therapy with beta-blockers or thiazide diuretics within the prior 3 months
Pregnancy, breastfeeding, or intention of becoming pregnant or judged to be using inadequate contraceptive measure.
Documented gastrointestinal disease, or taking of medications likely to alter gut motility or absorption.
Receiving any investigational drug within 30 days of the baseline visit.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00451477

Contacts

Contact: Randy Brown

301.957.4275

Show 24 Study Locations

Sponsors and Collaborators

BioSpherix

Spherix

More Information

No publications provided

Responsible Party:	Spherix ( Randy Brown, Chief of Operations )
Study ID Numbers:	70971-004
Study First Received:	March 21, 2007
Last Updated:	April 29, 2008
ClinicalTrials.gov Identifier:	NCT00451477 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Tagatose
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases

Chelating Agents
Endocrinopathy
Glucose Metabolism Disorders
Iron
Metabolic Disorder

Additional relevant MeSH terms:

Tagatose
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Diabetes Mellitus, Type 2
Iron Chelating Agents

Diabetes Mellitus
Endocrine System Diseases
Chelating Agents
Glucose Metabolism Disorders
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 02, 2009